Insmed to Host Second Quarter 2021 Financial Results Conference Call on Thursday, August 5, 2021
Insmed Incorporated (Nasdaq: INSM) will announce its Q2 2021 financial results on August 5, 2021. Management will host a conference call at 8:30 a.m. ET to discuss these results and provide a business update. Investors can join the call by dialing (844) 200-6205 (domestic) or +44-208-0682-558 (international), with an access code of 711350. The call will also be webcast live on their website. A replay will be available after the call and accessible until September 6, 2021. Insmed is focused on treating serious and rare diseases.
- Insmed is preparing to release its Q2 2021 financial results, indicating ongoing business activity.
- The upcoming conference call signifies that Insmed is engaging with investors.
- None.
BRIDGEWATER, N.J., July 27, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its second quarter 2021 financial results on Thursday, August 5, 2021.
Insmed management will host a conference call for investors beginning at 8:30 a.m. ET on Thursday, August 5, 2021 to discuss the financial results and provide a business update.
Shareholders and other interested parties may participate in the conference call by dialing (844) 200-6205 (domestic) or +44-208-0682-558 (international) and referencing access code 711350. The call will also be webcast live on the company's website at www.insmed.com.
A replay of the conference call will be accessible approximately 45 minutes after its completion through September 6, 2021 by dialing (929) 458-6194 (domestic) or +44-204-525-0658 (international) and referencing access code 984249. A webcast of the call will also be archived for 90 days under the Investor Relations section of the company's website at www.insmed.com.
About Insmed
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company is also progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is headquartered in Bridgewater, New Jersey, with a growing footprint across Europe and in Japan. For more information, visit www.insmed.com.
Contact:
Investors:
Eleanor Barisser
Associate Director, Investor Relations
Insmed
(718) 594-5332
eleanor.barisser@insmed.com
Media:
Mandy Fahey
Senior Director, Corporate Communications
Insmed
(732) 718-3621
amanda.fahey@insmed.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/insmed-to-host-second-quarter-2021-financial-results-conference-call-on-thursday-august-5-2021-301341359.html
SOURCE Insmed Incorporated
FAQ
When will Insmed announce its Q2 2021 financial results?
What time is the Insmed conference call for financial results?
How can I participate in the Insmed conference call?
What is the access code for the Insmed conference call?
Will there be a replay of the Insmed conference call?
